{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:35:38Z","timestamp":1773369338218,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.prrv.2008.11.003","type":"journal-article","created":{"date-parts":[[2009,4,10]],"date-time":"2009-04-10T08:23:16Z","timestamp":1239351796000},"page":"58-62","source":"Crossref","is-referenced-by-count":14,"title":["Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis"],"prefix":"10.1016","volume":"10","author":[{"given":"Israel","family":"Amirav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malena","family":"Cohen-Cymberknoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shoseyov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Kerem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2008.11.003_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3943","article-title":"Immotile cilia syndrome (primary ciliary dyskinesia) including Kartagener syndrome","author":"Afzelius","year":"1995"},{"key":"10.1016\/j.prrv.2008.11.003_bib2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.98.12040982","article-title":"Primary ciliary dyskinesia: diagnosis and standards of care","volume":"12","author":"Bush","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib3","series-title":"The Pediatric Lung.","first-page":"155","article-title":"Mucoactive agents: Old and new","author":"Rubin","year":"1997"},{"key":"10.1016\/j.prrv.2008.11.003_bib4","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1378\/chest.106.5.1532","volume":"106","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2008.11.003_bib5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1183\/09031936.96.09040725","article-title":"Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects","volume":"9","author":"Daviskas","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/ajrccm.156.1.9512074","article-title":"Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I","volume":"156","author":"King","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jpeds.2007.04.010","article-title":"Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants","volume":"151","author":"Kuzik","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.prrv.2008.11.003_bib10","doi-asserted-by":"crossref","unstructured":"Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006; 2:CD00299.","DOI":"10.1002\/14651858.CD002996.pub2"},{"key":"10.1016\/j.prrv.2008.11.003_bib11","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1183\/09031936.97.10112449","article-title":"Inhalation of dry-powder mannitol increases mucociliary clearance","volume":"10","author":"Daviskas","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib12","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1164\/ajrccm.159.6.9809074","article-title":"Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis","volume":"159","author":"Daviskas","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1183\/09031936.00119707","article-title":"Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis","volume":"31","author":"Daviskas","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijpharm.2007.08.013","article-title":"Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers","volume":"349","author":"Glover","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.prrv.2008.11.003_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM199004263221704","article-title":"A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis","volume":"322","author":"Knowles","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1002","article-title":"Amiloride inhalation therapy in cystic fibrosis","volume":"148","author":"Tomkiewicz","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.prrv.2008.11.003_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1183\/09031936.93.06091243","article-title":"No added benefit from nebulized amiloride in patients with cystic fibrosis","volume":"6","author":"Graham","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/thx.50.5.517","article-title":"An alternative aerosol delivery system for amiloride","volume":"50","author":"Everard","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2008.11.003_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.med.45.1.421","article-title":"Modulation of the ionic milieu of the airway in health and disease","volume":"45","author":"Noone","year":"1994","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/ajrccm.160.1.9806146","article-title":"Effect of aerosolized uridine-5\u2019-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia","volume":"160","author":"Noone","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.pupt.2007.12.003","article-title":"Denufosol: A review of studies with inhaled P2Y(2) agonists that led to Phase 3","volume":"21","author":"Kellerman","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.prrv.2008.11.003_bib22","first-page":"241","article-title":"Stodola FH Antibiotics against plant disease. IV. Activity of duramycin against selected microorganisms","volume":"5","author":"Lindenfelser","year":"1957","journal-title":"Antibiot Annu"},{"key":"10.1016\/j.prrv.2008.11.003_bib23","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1378\/chest.06-2085","article-title":"Inhalation of Moli1901 in patients with cystic fibrosis","volume":"131","author":"Grasemann","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2008.11.003_bib24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.160.5.9810080","article-title":"Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study","volume":"160","author":"Labiris","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib25","doi-asserted-by":"crossref","unstructured":"McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Bruce Montgomery A. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008 Jul 24.(epub ahead of print).","DOI":"10.1164\/rccm.200712-1804OC"},{"key":"10.1016\/j.prrv.2008.11.003_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1378\/chest.120.3_suppl.114S","article-title":"Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa","volume":"120","author":"Couch","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2008.11.003_bib28","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2008.11.003_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/jac\/27.3.285","article-title":"The diffusion of beta-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate","volume":"27","author":"Bolister","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.prrv.2008.11.003_bib31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib32","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(85)92929-0","article-title":"Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis","volume":"2","author":"Auerbach","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2008.11.003_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/adc.71.1.35","article-title":"Interleukin-1a, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone","volume":"71","author":"Greally","year":"1994","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.prrv.2008.11.003_bib34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.prrv.2008.11.003_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2008.11.003_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2008.11.003_bib37","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2008.06.005","article-title":"Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis","volume":"102","author":"Anwar","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1183\/09031936.99.13111499","article-title":"Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome","volume":"13","author":"Grasemann","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib40","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1183\/09031936.95.08101786","article-title":"RhDNase trials in cystic fibrosis","volume":"8","author":"Hodson","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2008.11.003_bib41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ppul.70090","article-title":"Dornase in non-CF","volume":"26","author":"Ratjen","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2008.11.003_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1378\/chest.129.1.118","article-title":"Mucus properties in children with primary ciliary dyskinesia. Comparison with cystic fibrosis","volume":"129","author":"Bush","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2008.11.003_bib43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.1950200509","article-title":"Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome","volume":"20","author":"Desai","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2008.11.003_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<59::AID-PPUL11>3.0.CO;2-D","article-title":"DNase treatment in primary ciliary dyskinesia\u2014assessment by nocturnal pulse oximetry","volume":"27","author":"Ten Berge","year":"1999","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2008.11.003_bib45","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.rmed.2007.05.014","article-title":"Long-term use of nebulized human recombinant DNase1 in two siblings with primary ciliary dyskinesia","volume":"101","author":"El-Abiad","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"O\u2019Donnell","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2008.11.003_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/ng1403","article-title":"Nonsense-mediated decay approaches the clinic","volume":"36","author":"Holbrook","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.prrv.2008.11.003_bib48","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib50","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJMoa022170","article-title":"Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations","volume":"349","author":"Wilschanski","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib52","first-page":"691","article-title":"PTC124 activity in CF patients carrying stop mutations: Interim results of phase 2 study","volume":"372","author":"Kerem","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2008.11.003_bib53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1164\/rccm.200601-084OC","article-title":"DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects","volume":"174","author":"Hornef","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2008.11.003_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng817","article-title":"Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry","volume":"30","author":"Olbrich","year":"2002","journal-title":"Nat Genet"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152605420800081X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152605420800081X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T20:19:01Z","timestamp":1684959541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152605420800081X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S152605420800081X"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2008.11.003","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}